CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $76.29 Consensus Target Price from Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP) has been given a consensus rating of “Hold” by the sixteen brokerages that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $76.29.

A number of analysts have recently issued reports on CRSP shares. Wells Fargo & Company increased their price target on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 22nd. TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 23rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, April 11th. Wolfe Research started coverage on CRISPR Therapeutics in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, Mizuho boosted their target price on CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $55.65 on Monday. CRISPR Therapeutics has a 52 week low of $37.55 and a 52 week high of $91.10. The firm has a market capitalization of $4.72 billion, a price-to-earnings ratio of -28.39 and a beta of 1.76. The company has a 50 day moving average price of $71.75 and a 200 day moving average price of $63.80.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The business had revenue of $201.20 million for the quarter, compared to analysts’ expectations of $148.72 million. The business’s quarterly revenue was up 3253.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.41) EPS. Equities analysts forecast that CRISPR Therapeutics will post -6.24 earnings per share for the current fiscal year.

Insider Activity

In other news, General Counsel James R. Kasinger sold 1,913 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the transaction, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 2,801 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $78.26, for a total transaction of $219,206.26. Following the completion of the sale, the general counsel now owns 60,070 shares of the company’s stock, valued at approximately $4,701,078.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 133,992 shares of company stock valued at $9,157,835. 4.10% of the stock is owned by insiders.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. ARK Investment Management LLC increased its holdings in CRISPR Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock valued at $534,360,000 after buying an additional 1,372,986 shares during the period. Capital International Investors boosted its position in shares of CRISPR Therapeutics by 0.8% during the 4th quarter. Capital International Investors now owns 6,134,450 shares of the company’s stock valued at $384,017,000 after acquiring an additional 48,938 shares in the last quarter. Vanguard Group Inc. increased its stake in CRISPR Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 1,590,651 shares of the company’s stock valued at $99,575,000 after acquiring an additional 51,926 shares during the period. Charles Schwab Investment Management Inc. raised its position in CRISPR Therapeutics by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 653,023 shares of the company’s stock worth $40,879,000 after purchasing an additional 15,085 shares in the last quarter. Finally, Norges Bank bought a new position in CRISPR Therapeutics during the fourth quarter worth about $38,661,000. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.